China Oncology ›› 2022, Vol. 32 ›› Issue (11): 1049-1064.doi: 10.19401/j.cnki.1007-3639.2022.11.003
• Specialists' Article • Previous Articles Next Articles
SHI Yue1(), CHEN Yiqing2(
), DING Jingxin1, NING Yan1, WANG Qing1, MA Fenghua1, TAN Haowen3, KANG Yu1(
)
Received:
2022-10-12
Revised:
2022-11-16
Online:
2022-11-30
Published:
2022-12-14
Contact:
KANG Yu
Share article
CLC Number:
SHI Yue, CHEN Yiqing, DING Jingxin, NING Yan, WANG Qing, MA Fenghua, TAN Haowen, KANG Yu. Questionnaire survey on current status of clinical screening and treatment of gynecological disease in females with Peutz-Jeghers syndrome[J]. China Oncology, 2022, 32(11): 1049-1064.
Tab. 1
Cohort characteristics of the study population [n (%)]"
Characteristic | Number of patients | Characteristic | Number of patients | |
---|---|---|---|---|
Current diagnosis | Have family members with similar conditions | 30 (20.13) | ||
Self-reported as healthy or unexamined | 119 (79.87) | Internet access to information | 43 (28.86) | |
Pre-cancer | 7 (15.43) | Others | 7 (4.70) | |
Cancer | 23 (4.70) | Monthly household income per capita/RMB | ||
Education level | ≤3 000 | 58 (38.93) | ||
Junior high school and below | 41 (27.52) | 3 000-7 000 | 73 (48.99) | |
Senior high school | 35 (23.49) | 7 000-20 000 | 17 (11.41) | |
University | 67 (44.97) | 20 000-37 000 | 1 (0.67) | |
Postgraduate and above | 6 (4.03) | >37 000 | 0 (0.00) | |
Source of information | Economic status of living region | |||
Being told from doctors | 104 (69.80) | Less developed regions | 80 (53.69) | |
Being told from patients with same conditions | 37 (24.83) | Developed regions (first and second tier cities) | 69 (46.31) | |
Have medical backgrounds | 25 (16.78) |
Tab. 2
Life history of PJS patients in this cohort [n (%)]"
Life history | Number of patients | Life history | Number of patients | |
---|---|---|---|---|
Smoking tobacco | Total | 131 (100.00) | ||
Yes | 12 (8.05) | Sexual activity | ||
No | 137 (91.95) | Yes | 110 (73.83) | |
Total | 149 (100.00) | No | 39 (26.17) | |
Drinking alcohol | Total | 149 (100.00) | ||
Yes | 21 (14.09) | Contraception | ||
No | 128 (85.91) | No contraception | 25 (22.73) | |
Total | 149 (100.00) | Condom | 67 (60.91) | |
Drinking tea | Intra uterine device | 20 (18.18) | ||
Yes | 38 (25.50) | Fallopian tube ligation | 2 (1.82) | |
No | 111 (74.50) | Oral contraceptive pills | 5 (4.55) | |
Total | 149 (100.00) | Total | 110 (100.00) | |
Menstrual history | Fertility history | |||
Menopausal or not | Yes | 64 (42.95) | ||
Yes | 18 (12.08) | No | 85 (57.05) | |
No | 131 (87.92) | Total | 149 (100.00) | |
Total | 149 (100.00) | Delivery | ||
Levels of dysmenorrhea | Natural birth | 33 (51.56) | ||
None | 47 (35.88) | Cesarean delivery | 17 (26.56) | |
Mild | 52 (39.69) | Spontaneous miscarriage | 2 (3.13) | |
Medium | 27 (20.61) | Abortion | 12 (18.75) | |
Severe | 5 (3.82) | Total | 64 (100.00) | |
Total | 131 (100.00) | PGT | ||
Amount of menstruation | Yes | 1 (1.56) | ||
Small | 15 (11.45) | No | 63 (98.44) | |
Medium | 96 (73.28) | Total | 64 (100.00) | |
Massive | 20 (15.27) |
Tab. 3
Past history of PJS patients in this cohort [n (%)]"
Past history | Number of patients | Past history | Number of patients | |
---|---|---|---|---|
Tumor history | Around lips | 136 (91.28) | ||
Yes | 23 (15.44) | Lower eyelid | 56 (37.58) | |
No | 126 (84.56) | Chest and back | 3 (2.01) | |
Total | 149 (100.00) | No black spots ever found | 2 (1.34) | |
Tumor treatment | Total | 149 (100.00) | ||
Surgical procedures | 22 (95.65) | Gastrointestinal polyps history | ||
Chemotherapy | 15 (65.21) | Yes | 149 (100.00) | |
Radiotherapy | 9 (39.13) | No | 0 (0.00) | |
Molecularly targeted therapy | 2 (8.70) | Total | 149 (100.00) | |
Immunotherapy | 2 (8.70) | Treatment | ||
Total | 23 (100.00) | Endoscopic surgery | 131 (87.92) | |
Current status | Abdominal surgery | 88 (59.06) | ||
Complete response | 5 (21.74) | Regular endoscopy | 23 (15.44) | |
Partial response | 1 (4.34) | Laparoscopic surgery | 11 (7.38) | |
Stable disease | 11 (47.83) | Medication | 3 (2.01) | |
Progressive disease | 4 (17.39) | Untreated | 1 (0.67) | |
Death | 2 (8.70) | Total | 149 (100.00) | |
Total | 23 (100.00) | Surgical history (except gynecological procedures) | ||
Dark spot history | Yes | 87 (58.39) | ||
Yes | 147 (98.66) | No | 62 (41.61) | |
No | 2 (1.34) | Total | 149 (100.00) | |
Total | 149 (100.00) | Gynecological surgery history | ||
Body parts | Yes | 44 (29.53) | ||
Oral mucosa | 137 (91.95) | No | 105 (70.47) | |
Hands and feet | 136 (91.28) | Total | 149 (100.00) |
Tab. 5
Gynecology-related complaints and related tests of PJS patients in this cohort [n (%)]"
Item | Number of patients | Item | Number of patients | |
---|---|---|---|---|
Gynecology-related complaints | Total | 35 (100.00) | ||
Irregular menstrual periods | 83 (55.70) | Radiographic examination | ||
Watery vaginal discharge | 62 (41.61) | Ultrasound | 110 (73.83) | |
Pruritus of vagina or vulva | 46 (30.87) | CT | 93 (62.42) | |
Abdominal pain or distention | 44 (29.53) | MRI | 34 (22.82) | |
No significant symptoms | 35 (23.49) | PET/CT | 12 (8.05) | |
Intercourse bleeding | 25 (16.78) | No examination has been performed | 36 (24.16) | |
Total | 149 (100.00) | Total | 149 (100.00) | |
HPV test: perform | Tumor markers | |||
Yes | 71 (47.65) | Yes | 53 (35.57) | |
No | 78 (52.35) | No | 96 (64.43) | |
Total | 149 (100.00) | Total | 149 (100.00) | |
HPV test results | Genetic test | |||
Positive | 5 (7.04) | Yes | 55 (36.91) | |
Negative | 66 (92.96) | No | 94 (63.09) | |
Total | 71 (100.00) | Total | 149 (100.00) | |
TCT: perform | STK11 mutation | |||
Yes | 35 (43.75) | Positive | 52 (94.55) | |
No | 45 (56.25) | Negative | 3 (5.45) | |
Total | 80 (100.00) | Total | 55 (100.00) | |
TCT results | Combining other mutations | |||
NILM | 31 (88.57) | Yes | 7 (14.00) | |
LSIL | 0 (0.00) | No | 43 (86.00) | |
HSIL | 0 (0.00) | Total | 50 (100.00) | |
Cancer cells | 4 (11.43) |
Tab. 6
Specific manifestations of irregular menstruation in PJS patients in this cohort [n (%)]"
Specific manifestation | Number of patients |
---|---|
Uncertain intermenstrual interval | 53 (67.09) |
Long intermenstrual interval (≥40 d) | 29 (36.71) |
Short intermenstrual interval (≤20 d) | 10 (12.66) |
Uncertain menstrual volume | 30 (37.97) |
Long menstrual volume | 18 (22.78) |
Short menstrual volume | 11 (13.92) |
Menopause for six months or more | 5 (6.33) |
Tab. 8
Diagnosis and treatment of 15 PJS patients with GAS in this cohort"
Case | Age/year | G | P | Menopause | Watery discharge | Pathology | Surgery | Adjuvant therapy |
---|---|---|---|---|---|---|---|---|
1 | 34 | 0 | 0 | Pre | - | Ovarian mucinous cancer, GAS, EEC G1 (SMMN-FGT) | TH + BSO | - |
2 | 43 | 0 | 0 | Pre | + | GAS | TH + BSO | + |
3 | 50 | 3 | 1 | post | + | Ovarian mucinous cancer, GAS (SMMN-FGT) | TH + BSO + PVLN | + |
4 | 35 | 2 | 1 | Pre | - | GAS | TH + BSO | + |
5 | 43 | 2 | 1 | Pre | + | GAS | RH + BSO + PVLN + PALN | + |
6 | 29 | 0 | 0 | Pre | - | GAS | TH + BSO | + |
7 | 32 | 0 | 0 | Pre | + | GAS | RH + BSO + PVLN + PALN | + |
8 | 53 | 1 | 1 | Post | + | GAS | RH + BSO + PVLN + PALN | - |
9 | 46 | 0 | 0 | Post | + | GAS | TH + BSO | + |
10 | 35 | 2 | 1 | Pre | - | Ovarian mucinous cancer, GAS (SMMN-FGT) | TH + BSO | + |
11 | 41 | 6 | 2 | Pre | + | GAS | RH + BSO + PVLN + PALN + omentectomy | + |
12 | 28 | 0 | 0 | Pre | + | GAS | RH + BSO + PVLN + PALN + omentectomy | - |
13 | 40 | 0 | 0 | Pre | - | GAS | TH + bilateral salpingectomy | - |
14 | 28 | 0 | 0 | Pre | + | GAS, AEH (SMMN-FGT) | RH + BSO + PVLN + PALN + omentectomy | + |
15 | 31 | 0 | 0 | Pre | - | GAS, AEH (SMMN-FGT) | RH + BSO + PVLN + PALN | + |
Tab. 9
Six PJS patients with atypical LEGH"
Case | Age/year | G | P | Menopause | Watery discharge | Pathology | Surgery |
---|---|---|---|---|---|---|---|
1 | 28 | 0 | 0 | Pre | - | Atypical LEGH | LEEP |
2 | 30 | 3 | 1 | Pre | + | Atypical LEGH | TH+BSO |
3 | 15 | 0 | 0 | Pre | + | LEGH | Colposcopic biopsy |
4 | 11 | 0 | 0 | Pre | + | LEGH | Colposcopic biopsy |
5 | 38 | 1 | 1 | Pre | + | LEGH | LEEP |
6 | 37 | 1 | 1 | Pre | + | LEGH | LEEP |
Fig. 5
MRI of LEGH case 2 A: Sagittal section; B: Axial section. The uterus presents anterior flexion, and the size of the uterus was 5.4 cm×6.2 cm×4.0 cm. The endometrium was not thickened, without obvious abnormal signal. The cervix had a mass shadow with multiple cysts, the size was about 3.9 cm×3.0 cm×2.8 cm, uneven enhancement was seen after enhancement, and no obvious abnormal signal foci were seen around the uterus. There were no obvious abnormalities in bilateral ovaries and bilateral appendage areas. The bladder was well filled, the bladder wall is not thickened, and there was no obvious abnormal signal shadow on the bladder wall. There was no obvious abnormal signal shadow in the vagina, urethra and rectum. No lymph node abnormality was seen. A small amount of free fluid signal in recto-uterine pouch."
Tab. 10
STK11 gene mutations of 30 PJS female patients in this cohort"
Case | E/I | Domain | cDNA change | Protein change | Mutation type | History of tumor | Age of onset/year |
---|---|---|---|---|---|---|---|
1 | E5 | Ⅷ, Ⅸ | c.644delG | p.G215Afs*72 | Truncation | LEGH | 38 |
2 | I4 | Ⅶ | c.598-2A>G | Truncation | No cancer | ||
3 | I4 | Ⅶ | c.598-2A>G | Truncation | EC and GAS | 30 | |
4 | I6 | Ⅺ | c.863-8_870del | p.Met289fs | Truncation | No cancer | |
5 | E7 | Ⅺ | c.866T>G | p.M289R | Non-truncation | Breast cancer and thyroid cancer | 42 |
6 | E7 | Ⅺ | c.891G>C | p.R297S | Non-truncation | Watery vaginal discharge | |
7 | E1 | Ⅰ | c.160delC | p.L54Cfs*10 | Truncation | Watery vaginal discharge | |
8 | E1 | Ⅰ | c.206C>A (novel) | p.Ser69* | Truncation | No cancer | |
9 | E7 | Ⅺ | c.897_898insATCCGGCAG (novel) | p.Q305_H306insIRQ | Non-truncation | No cancer | |
10 | E1 | Ⅱ | c.250A>T | p.Lys84* | Truncation | GAS | 28 |
11 | E1 | Ⅱ | c.250A>T | p.Lys84* | Truncation | LEGH | 32 |
12 | E4 | ⅥB | c.539_560del22nt (novel) | p.G180Vfs*100 | Truncation | GAS | 42 |
13 | E7 | Ⅺ | c.877G>T | p.E293X | Non-truncation | No cancer | |
14 | E4 | ⅥB | c.A527G | p.D176G | Non-truncation | Ovarian cancer | 33 |
15 | E4 | Ⅶ | c.G580A | p.D194N | Non-truncation | Atypical LEGH | 31 |
16 | E1-E10 | Ⅰ-Ⅺ | 19p13.3 (1160000-1250000del) | Truncation | No cancer | ||
17 | E7 | Ⅺ | c.910C>T | p.R304W | Non-truncation | No cancer | |
18 | E4 | ⅥB | c.540delG | p.G180Gfs* | Truncation | No cancer | |
19 | E1-E10 | Ⅰ-Ⅺ | E1-10 del | Truncation | No cancer | ||
20 | E1-E11 | Ⅰ-Ⅺ | E1-E11 del | Truncation | Gastric cancer | 23 | |
21 | E4 | ⅥB | c.518delT (novel) | p.Val173Glyfs*114 | Truncation | No cancer | |
22 | E1 | Ⅰ-Ⅱ | del exon1 | Truncation | No cancer | ||
23 | E6 | Ⅺ | c.843dup | p.P281Pfs*4 | Truncation | No cancer | |
24 | E1-E3 | Ⅰ-ⅥA | E1-E3del | Truncation | LEGH | 15 | |
25 | E2-E6 | Ⅲ-Ⅺ | E2-E6del | Truncation | LEGH | 18 | |
26 | E7 | Ⅺ | c.890G>A | p.R297K | Non-truncation | LEGH | 26 |
27 | I7 | Ⅺ | c.921-1G>C (novel) | p.Arg297Ser | Non-truncation | GAS | 28 |
28 | E5 | Ⅶ | c.598_602del | p.A200fs | Truncation | GAS | 42 |
29 | E8 | Ⅺ | c.998_1002delCAGC | p.Arg333fs | Truncation | GAS | 26 |
30 | E5 | Ⅷ | c.658C>T | p.Gln220Ter | Non-truncation | GAS | 36 |
[1] |
GIARDIELLO F, TRIMBATH J. Peutz-Jeghers syndrome and management recommendations[J]. Clin Gastroenterol Hepatol, 2006, 4(4): 408-415.
doi: 10.1016/j.cgh.2005.11.005 |
[2] | 李白容, 孙涛, 蒋宇亮, 等. Peutz-Jeghers综合征发病机制及临床诊治研究进展[J]. 世界华人消化杂志, 2019, 27(9): 576-582. |
[3] | LI B R, SUN T, JIANG Y L, et al. Pathogenesis, diagnosis, and treatment of Peutz-Jeghers syndrome[J]. World Chin J Dig, 2019, 27(9): 576-582. |
[4] |
KHANNA K, KHANNA V, BHATNAGAR V. Peutz-Jeghers syndrome: need for early screening[J]. BMJ Case Rep, 2018, 11(1): e225076.
doi: 10.1136/bcr-2018-225076 |
[5] |
VAN LIER M G, WAGNER A, MATHUS-VLIEGEN E M, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations[J]. Am J Gastroenterol, 2010, 105(6): 1258-1264;
doi: 10.1038/ajg.2009.725 pmid: 20051941 |
[6] |
WAGNER A, ARETZ S, AURANEN A, et al. The management of Peutz-Jeghers syndrome: European hereditary tumour group (EHTG) guideline[J]. J Clin Med, 2021, 10(3): 473.
doi: 10.3390/jcm10030473 |
[7] |
LATCHFORD A, COHEN S, AUTH M, et al. Management of Peutz-Jeghers syndrome in children and adolescents: a position paper from the ESPGHAN polyposis working group[J]. J Pediatr Gastroenterol Nutr, 2019, 68(3): 442-452.
doi: 10.1097/MPG.0000000000002248 |
[8] | 薛誉, 石月, 徐言, 等. 妇科肿瘤诊疗中遗传咨询开展现状的问卷调查[J]. 第二军医大学学报, 2021, 42(6): 641-650. |
[9] | XUE Y, SHI Y, XU Y, et al. Questionnaire survey on status quo of genetic counseling on gynecologic tumors[J]. Acad J Second Mil Med Univ, 2021, 42(6): 641-650. |
[10] |
FREY M K, LEE S S, GERBER D, et al. Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression[J]. Gynecol Oncol, 2020, 157(1): 280-286.
doi: S0090-8258(20)30007-X pmid: 32057464 |
[11] |
FARHAN M. Green tea catechins: nature’s way of preventing and treating cancer[J]. Int J Mol Sci, 2022, 23(18): 10713.
doi: 10.3390/ijms231810713 |
[12] |
BEGGS A D, LATCHFORD A R, VASEN H F, et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management[J]. Gut, 2010, 59(7): 975-986.
doi: 10.1136/gut.2009.198499 pmid: 20581245 |
[13] |
ISHIDA H, TAJIMA Y, GONDA T, et al. Update on our investigation of malignant tumors associated with Peutz-Jeghers syndrome in Japan[J]. Surg Today, 2016, 46(11): 1231-1242.
doi: 10.1007/s00595-015-1296-y pmid: 26746637 |
[14] |
FADARE O. Mucinous proliferations of the uterine corpus: comprehensive appraisal of an evolving spectrum of neoplasms[J]. Adv Anat Pathol, 2022, 29(5): 275-296.
doi: 10.1097/PAP.0000000000000348 pmid: 35499137 |
[15] |
MIKAMI Y. Gastric-type mucinous carcinoma of the cervix and its precursors-historical overview[J]. Histopathology, 2020, 76(1): 102-111.
doi: 10.1111/his.13993 |
[16] | 顾伟勇, 陶祥, 张丽虹, 等. 女性生殖道同期发生的黏液上皮化生和肿瘤[J]. 中华病理学杂志, 2018, 47(11): 845-850. |
[17] | GU W Y, TAO X, ZHANG L H, et al. Synchronous mucinous metaplasia and neoplasia of the female genital tract[J]. Chin J Pathol, 2018, 47(11): 845-850. |
[18] | 陈默, 李佳佳, 陶祥, 等. 女性生殖道同期发生的黏液性上皮化生和肿瘤14例分析[J]. 复旦学报(医学版), 2022, 49(3): 402-410. |
[19] | CHEN M, LI J J, TAO X, et al. Clinical analysis of 14 cases of synchronous mucinous metaplasia and neoplasia of the female genital tract[J]. Fudan Univ J Med Sci, 2022, 49(3): 402-410. |
[20] | ABU-RUSTUM N R, YASHAR C M, BEAN S, et al. Cervical cancer, version 1. 2021 NCCN clinical practice guidelines in oncology[EB/OL]. (2020-10-02)[2022-05-10]. |
[21] |
周晖, 刘昀昀, 罗铭, 等. 《2021 NCCN子宫颈癌临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2020, 36(11): 1098-1104.
doi: 10.19538/j.fk2020110115 |
[22] | ZHOU H, LIU Y Y, LUO M, et al. Interpretation of the NCCN clinical practice guidelines for cervical cancer(2021.v1)[J]. Chin J Pract Gynecol Obstet, 2020, 36(11): 1098-1104. |
[23] |
TUNG N, LIN N U, KIDD J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer[J]. J Clin Oncol, 2016, 34(13): 1460-1468.
doi: 10.1200/JCO.2015.65.0747 pmid: 26976419 |
[24] |
LIM W, OLSCHWANG S, KELLER J J, et al. Relative frequency and morphology of cancers in STK11 mutation carriers[J]. Gastroenterology, 2004, 126(7): 1788-1794.
doi: 10.1053/j.gastro.2004.03.014 |
[25] |
MEHENNI H, RESTA N, PARK J G, et al. Cancer risks in LKB1 germline mutation carriers[J]. Gut, 2006, 55(7): 984-990.
doi: 10.1136/gut.2005.082990 |
[26] |
WANG Z Q, WANG Z, WANG Y, et al. High risk and early onset of cancer in Chinese patients with Peutz-Jeghers syndrome[J]. Front Oncol, 2022, 12: 900516.
doi: 10.3389/fonc.2022.900516 |
[27] |
HEARLE N, SCHUMACHER V, MENKO F H, et al. STK11 status and intussusception risk in Peutz-Jeghers syndrome[J]. J Med Genet, 2006, 43(8): e41.
doi: 10.1136/jmg.2005.040535 pmid: 16882735 |
[28] |
RESTA N, PIERANNUNZIO D, LENATO G M, et al. Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: results of an Italian multicenter study[J]. Dig Liver Dis, 2013, 45(7): 606-611.
doi: 10.1016/j.dld.2012.12.018 |
[1] | MA Fenghua, JIANG Anqi, CHEN Yiqing, XU Congjian, KANG Yu. Magnetic resonance imaging for distinguishing gastric-type endocervical adenocarcinoma from lobular endocervical glandular hyperplasia [J]. China Oncology, 2024, 34(4): 380-388. |
[2] | HU Hongfeng, LU Renquan, HU Juan, et al. The value of serum sialic acid levels detection in ovarian cancer [J]. China Oncology, 2017, 27(7): 588-592. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd